HOLON, Israel, April 27,
2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN)
(TASE:CGEN), a clinical-stage cancer immunotherapy company and a
pioneer in computational target discovery, today announced that it
will present new clinical data on COM701 in triple combination with
BMS-986207 (anti-TIGIT) and nivolumab in metastatic endometrial
cancer at the American Society of Clinical Oncology (ASCO) annual
meeting on June 2-6, 2023, in
Chicago, Illinois.
Poster Presentation Details:
Title: Preliminary antitumor activity of the combination
of COM701 + BMS-986207 + nivolumab in patients with recurrent,
metastatic MSS endometrial cancer
Abstract Number: 5595
Session Title: Gynecologic Cancer
Lead Author: Rasco, D, MD
Date: Monday, June 5, 2023
About Compugen
Compugen is a clinical-stage
therapeutic discovery and development company utilizing its broadly
applicable predictive computational discovery capabilities to
identify new drug targets and biological pathways for developing
cancer immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bi-specific derived from COM902, that is in
Phase 2 development by AstraZeneca through a license agreement for
the development of bi-specific and multi-specific
antibodies. In addition, the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of programs
aiming to address various mechanisms of immune resistance. The most
advanced program, COM503 is advancing in IND enabling
studies. COM503 is a potential first-in-class, high affinity
antibody which blocks the interaction between IL-18 binding protein
and IL-18, thereby freeing natural IL-18 to inhibit cancer growth
in the tumor microenvironment. Compugen is headquartered in
Israel, with offices in
San Francisco,
CA. Compugen's shares are listed on Nasdaq and the Tel
Aviv Stock Exchange under the ticker symbol CGEN.
Company contact:
Yvonne
Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-present-new-clinical-data-showing-preliminary-anti-tumor-activity-of-com701-triple-combination-in-recurrent-mss-metastatic-endometrial-cancer-at-asco-2023-301809359.html
SOURCE Compugen Ltd.